Expand CNSP Menu
CNSP MENU

CNSP Stock Posts


CNSP #CNSPharmaceuticals stock declines -57.4% in premarket,

Premarket Decliner

CNSP CNS Pharmaceuticals3.38-0.33-8.9%

Premarket:1.44-1.94 (-57.4%)

CNS Pharmaceuticals Announces Primary Analysis of Berubicin in Second Line Treatment of Glioblastoma Multiforme

ACCESS NewswireTue, 25-Mar 8:02 AM
CNSP #CNSPharmaceuticals stock increases 24.9% in premarket,

Premarket Gainer

CNSP CNS Pharmaceuticals2.01-0.06-2.9%

Premarket:2.51+0.50 (+24.9%)

FDA Grants Fast Track Designation to CNS Pharmaceuticals for Berubicin for the Treatment of Recurrent Glioblastoma Multiforme

PRNewswireTue, 29-Jun 8:35 AM
CNSP #CNSPharmaceuticals stock increases 49.6% in premarket,

Premarket Gainer

CNSP CNS Pharmaceuticals2.50+0.32+14.7%

Premarket:3.74+1.24 (+49.6%)

CNS Pharmaceuticals Announces Call to Discuss FDA IND Approval and Phase 2 Trial for Berubicin

PRNewswireThu, 17-Dec 4:05 PM
CNSP #CNSPharmaceuticals stock increases 40.4% in premarket,

Premarket Gainer

CNSP CNS Pharmaceuticals2.18-0.11-4.8%

Premarket:3.06+0.88 (+40.4%)

CNS Pharmaceuticals Announces FDA Approval of IND Application for its Brain Cancer Drug Candidate Berubicin

PRNewswireThu, 17-Dec 9:00 AM
Load Earlier Posts
Market Data Delayed 15 Minutes